Dariohealth presents new clinical research demonstrating improved outcomes for participants using a single integrated digital solution to manage multiple chronic conditions

New research offers fresh evidence that a single digital therapeutics platform can improve outcomes for commonly co-occurring conditions new york , april 27, 2022 /prnewswire/ -- dariohealth corp. (nasdaq: drio), a leader in the global digital therapeutics (dtx) market, announced the publication of a retrospective, real-world study demonstrating the impact of managing diabetes and weight together on a single digital platform at the advanced technologies and treatments for diabetes (attd) conference being held april 27 th – 30th in barcelona and online. to better understand the impact of an integrated, multi-condition digital therapeutics platform, dario analyzed 12 months of real-world retrospective data for a group of 715 individuals using the dario app to manage their blood sugar and demonstrating a body mass index (bmi) of greater than 30 kg/m2, the clinical baseline for obesity.
DRIO Ratings Summary
DRIO Quant Ranking